MedTrace Logo

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-04-13

Study results available
· View outcomes & findings →

Summary

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

Conditions

Interventions

DRUG

(CP-6890,550) Tofacitinib

2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

DRUG

Placebo

2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

DRUG

(CP-690,550) Tofacitinib

2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks

DRUG

Placebo

2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01710046 on ClinicalTrials.gov